Dr Priya Sammani ( MBBS ,DFM )It’s a moment that can feel overwhelming – hearing the words "tuberculosis" or "TB." Your mind might race with questions, and that's completely normal. #Bedaquiline #lunginfection #multidrugresistantTB #Sirturo #TBtreatment #Tuberculosis
Gabriele PollaraOk this is alarming:
Emergence of bedaquiline-resistant tuberculosis and of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains with rpoB Ile491Phe mutation not detected by Xpert MTB/RIF in Mozambique: a retrospective observational study
#TB #AMR #antibiotics #bedaquiline #MDRTB #tuberculosis #IDMastodon #infectiousdiseases
Look at all those acquisitions of #bedaquiline resistance (red dots) after using it (green bars) for treatment of #MDRTB
#TB #tuberculosis #AMR #infectiousdiseases #IDMastodon #medicine #antibiotics
Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study
ehwoza#TB - Johnson & Johnson has agreed to drop the price of #bedaquiline to the South African government by more than 40%. https://www.groundup.org.za/article/life-saving-tb-drug-now-cheaper-in-south-africa-but-not-as-cheap-as-it-can-be/
IndiaNewsWatchAfter Decades of Pressure, US Drugmaker J&J Gives Up Patent on Life-Saving TB Drug
This move can lead to the entry of many manufacturers of bedaquiline, thereby reducing the exorbitant price which many governments currently find difficult to afford for all of their patients, say activists.
#tuberculosis #JohnsonAndJohnson #bedaquiline #sirturo #DrugResistantTB #DRTB #LMICs #DrugPatents #drugs #medicine #health #healthcare #india
MarathonThey're no Jonas #Salk, but this is nice: https://www.jnj.com/johnson-johnson-confirms-intent-not-to-enforce-patents-for-sirturo-bedaquiline-for-the-treatment-of-multidrug-resistant-tuberculosis-in-134-low-and-middle-income-countries
#tuberculosis
#Bedaquiline
#tuberculosis
#Bedaquiline
Johnson & Johnson Confirms Intent Not to Enforce Patents for SIRTURO® (bedaquiline) for the Treatment of Multidrug-Resistant Tuberculosis in 134 Low- and Middle-Income Countries | Johnson & Johnson
Company continues to be focused on addressing perceived barriers to access and refocusing global efforts on the most-pressing barrier to access: underdiagnosis of the disease.Decision builds on a decade of Company investments in collaborative efforts to help countries sustainably scale up access and bring people living with multidrug-resistant tuberculosis (MDR-TB) into treatment.
Rad 💛🤍💜🖤What a #Pizzamas this is becoming! J&J relinquish the #bedaquiline patent, #AFCWimbledon finally win at home with a thumping hat-trick from al Hamadi, and we're still in the first week!
Norobiik @"While #JohnsonAndJohnson’s main patent for #bedaquiline expired in July, it had faced criticism for using secondary patents – in which small modifications are made to a product to extend a #patent and prevent a product from being sold by competitors." #GenericDrugs
Cost of #tuberculosis treatment halved in deal to permit generic versions | Global development | The Guardian
https://www.theguardian.com/global-development/2023/aug/31/cost-of-tuberculosis-treatment-halved-in-deal-to-permit-generic-versions
"The #GlobalPatent of the drug ends on Tuesday 18 July, but in a number of countries Johnson & Johnson continues to control the market with #SecondaryPatents – for which small modifications are made to a product to extend a patent.
J&J’s decision will allow the Stop #Tuberculosis Partnership coalition to procure and supply generic #bedaquiline to 44 low- and middle-income countries" #GenericDrugs
Cheaper TB drugs for millions after global deal on patent rights agreed
Zane SelvansWell holy shit that was fast.
The Good News Video
I mean...wow...a lot happening here. It's worth saying that Johnson & Johnson could have completely abandoned their patent, but they did not. That means that...